$EONR
EON Resources Inc. Stock $eonr

$eonr Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023069060 Filed on August 18, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$426.8K	$441.6K
YoY Change
% of Gross Profit
Operating Expenses	$710.0K	$660.0K	$599.6K
YoY Change	54.58%	10.07%
Operating Profit	-$708.7K	-$664.7K	-$599.6K
YoY Change	54.31%	10.86%	19987266.67%
Interest Expense	$89.77K	$780.0K	$118.9K
YoY Change	-77.43%	555.85%
% of Operating Profit
Other Income/Expense, Net	$497.6K	$579.3K	$118.9K
YoY Change	25.13%	387.14%
Pretax Income	-$211.1K	-$85.41K	-$480.7K
YoY Change	242.58%	-82.23%
Income Tax	-$205.8K	$147.4K
% Of Pretax Income
Net Earnings	-$5.358K	-$232.8K	-$480.7K
YoY Change	-91.31%	-51.57%	16023100.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	-$0.02	-$41.33K
COMMON SHARES
Basic Shares Outstanding	7.516M shares	7.516M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$640.0K	$810.0K	$326.3K
YoY Change	1117.89%	148.28%
Cash & Equivalents	$638.7K	$813.2K	$326.2K
Short-Term Investments
Other Short-Term Assets	$50.00K	$0.00	$330.3K
YoY Change	-75.34%	-100.0%
Inventory
Prepaid Expenses	$50.00K		$330.2K
Receivables
Other Receivables
Total Short-Term Assets	$688.7K	$813.2K	$656.5K
YoY Change	169.81%	23.87%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$48.97M	$48.11M	$88.10M
YoY Change	-44.67%	-45.39%
Other Assets	$150.0K
YoY Change
Total Long-Term Assets	$49.12M	$48.11M	$88.10M
YoY Change	-44.49%	-45.4%
TOTAL ASSETS
Total Short-Term Assets	$688.7K	$813.2K	$656.5K
Total Long-Term Assets	$49.12M	$48.11M	$88.10M
Total Assets	$49.81M	$48.92M	$88.76M
YoY Change	-43.88%	-44.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.540M	$1.150M	$232.4K
YoY Change	542.01%	394.88%
Accrued Expenses	$470.0K	$1.150M	$232.4K
YoY Change	95.94%	394.93%
Deferred Revenue
YoY Change
Short-Term Debt	$1.520M	$930.0K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.678M	$3.170M	$332.4K
YoY Change	1356.29%	853.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.440M	$4.050M	$2.588M
YoY Change	-5.7%	56.52%
Total Long-Term Liabilities	$2.439M	$4.047M	$2.588M
YoY Change	-5.75%	56.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.678M	$3.170M	$332.4K
Total Long-Term Liabilities	$2.439M	$4.047M	$2.588M
Total Liabilities	$8.116M	$7.217M	$2.920M
YoY Change	172.6%	147.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.896M	-$5.747M	-$2.137M
YoY Change	168.08%	168.97%
Common Stock	$301.00	$301.00	$301.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.896M	-$5.746M	-$2.136M
YoY Change
Total Liabilities & Shareholders Equity	$49.81M	$48.92M	$88.76M
YoY Change	-43.88%	-44.88%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.358K	-$232.8K	-$480.7K
YoY Change	-91.31%	-51.57%	16023100.0%
Depreciation, Depletion And Amortization	$426.8K	$441.6K
YoY Change
Cash From Operating Activities	-$520.0K	-$450.0K	-$283.0K
YoY Change	89.99%	59.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$240.0K	$43.79M	$0.00
YoY Change
Cash From Investing Activities	-$240.0K	$43.79M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	580.0K	-42.64M	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-520.0K	-450.0K	-283.0K
Cash From Investing Activities	-240.0K	43.79M	0.000
Cash From Financing Activities	580.0K	-42.64M	0.000
Net Change In Cash	-180.0K	700.0K	-283.0K
YoY Change	-34.23%	-347.35%
FREE CASH FLOW
Cash From Operating Activities	-$520.0K	-$450.0K	-$283.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2023Q2	hnra	Diluted Net Loss Per Redeemable Common Stock DilutedNetLossPerRedeemableCommonStock	0.02
	hnra	Diluted Net Loss Per Redeemable Common Stock DilutedNetLossPerRedeemableCommonStock	0.03
CY2022Q2	hnra	Diluted Net Loss Per Nonredeemable Common Stock DilutedNetLossPerNonredeemableCommonStock	-0.05
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39718
	dei	Entity Registrant Name EntityRegistrantName	HNR ACQUISITION CORP
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-4359124
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3730 Kirby Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77098
	dei	City Area Code CityAreaCode	(713)
	dei	Local Phone Number LocalPhoneNumber	834.1145
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7515653	shares
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	813177	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75612	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	81914	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	813177	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	157526	usd
CY2023Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	48106123	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	89243362	usd
CY2023Q2	us-gaap	Assets Assets	48919300	usd
CY2022Q4	us-gaap	Assets Assets	89400888	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1150132	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	395550	usd
CY2023Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	557774	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	221665	usd
CY2023Q2	hnra	Franchise Tax Payable FranchiseTaxPayable	100000	usd
CY2022Q4	hnra	Franchise Tax Payable FranchiseTaxPayable	200000	usd
CY2023Q2	hnra	Excise Tax Payables ExciseTaxPayables	436665	usd
CY2023Q2	hnra	Due To Other Related Parties Current DueToOtherRelatedPartiesCurrent	925654	usd
CY2022Q4	hnra	Due To Other Related Parties Current DueToOtherRelatedPartiesCurrent	129000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3170225	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	946215	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1459691	usd
CY2023Q2	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2587500	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	2587500	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4047191	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2587500	usd
CY2023Q2	us-gaap	Liabilities Liabilities	7217416	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3533715	usd
CY2023Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4509403	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	8625000	shares
CY2023Q2	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.52
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.32
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	47448349	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	89043362	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3006250	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3006250	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3006250	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3006250	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	301	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	301	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5746766	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3176490	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-5746465	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3176189	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48919300	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89400888	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	614748	usd
CY2022Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	499621	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1268479	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	806041	usd
CY2023Q2	us-gaap	Taxes Other TaxesOther	50000	usd
CY2022Q2	us-gaap	Taxes Other TaxesOther	100000	usd
	us-gaap	Taxes Other TaxesOther	100000	usd
	us-gaap	Taxes Other TaxesOther	100000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-664748	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-599621	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1368479	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-906041	usd
CY2023Q2	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	842756	usd
CY2022Q2	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	118795	usd
	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	1789672	usd
	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	127088	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-113469	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-92713	usd
CY2023Q2	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-314479	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-499058	usd
CY2023Q2	us-gaap	Dividend Income Operating DividendIncomeOperating	2262	usd
CY2022Q2	us-gaap	Dividend Income Operating DividendIncomeOperating	130	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	4001	usd
	us-gaap	Dividend Income Operating DividendIncomeOperating	130	usd
CY2023Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	64671	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	93156	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	579337	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	118925	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1294172	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	127218	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-85411	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-480696	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-74307	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-778823	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	147392	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	336110	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-232803	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-480696	usd
	us-gaap	Net Income Loss NetIncomeLoss	-410417	usd
	us-gaap	Net Income Loss NetIncomeLoss	-778823	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3176189	usd
CY2023Q1	hnra	Temporary Equity Accretion To Remeasurement Of Redeemable Common Stock To Redemption Value TemporaryEquityAccretionToRemeasurementOfRedeemableCommonStockToRedemptionValue	1759415	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-177614	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-5113218	usd
CY2023Q2	hnra	Temporary Equity Accretion To Remeasurement Of Redeemable Common Stock To Redemption Value TemporaryEquityAccretionToRemeasurementOfRedeemableCommonStockToRedemptionValue	-36221	usd
CY2023Q2	hnra	Excise Tax Imposed On Common Stock Redemptions ExciseTaxImposedOnCommonStockRedemptions	-436665	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-232803	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-5746465	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	111218	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5023384	usd
CY2022Q1	hnra	Fair Value Of Public Warrants FairValueOfPublicWarrants	5879729	usd
CY2022Q1	hnra	Offering Costs Allocated To Public Warrants OfferingCostsAllocatedToPublicWarrants	-30989	usd
CY2022Q1	hnra	Temporary Equity Accretion To Remeasurement Of Redeemable Common Stock To Redemption Value TemporaryEquityAccretionToRemeasurementOfRedeemableCommonStockToRedemptionValue	12340822	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-298127	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1655607	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-480696	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-2136303	usd
	us-gaap	Net Income Loss NetIncomeLoss	-410417	usd
	us-gaap	Net Income Loss NetIncomeLoss	-778823	usd
	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	1789672	usd
	us-gaap	Interest Income Securities Other Us Government InterestIncomeSecuritiesOtherUSGovernment	127088	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-92713	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	499058	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-81914	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	330246	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	754582	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	169309	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	336109	usd
	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	-100000	usd
	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-721139	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-966848	usd
	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund	43318207	usd
	hnra	Interest Withdrawn From Trust Account To Pay For Franchise And Federal Income Taxes InterestWithdrawnFromTrustAccountToPayForFranchiseAndFederalIncomeTaxes	711204	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1102500	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	87975000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42926911	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87975000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	84319667	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5023384	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	25500	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1850000	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-88200	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	43318207	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-41468207	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	89229351	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	737565	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	287503	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75612	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38743	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	813177	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	326246	usd
	hnra	Deferred Offering Cost Paid Directly By Related Party DeferredOfferingCostPaidDirectlyByRelatedParty	1552404	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1723194	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	12340822	usd
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2587500	usd
	us-gaap	Stock Issued1 StockIssued1	436665	usd
	hnra	Description Of Organization And Business Operations DescriptionOfOrganizationAndBusinessOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Organization and General:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HNR Acquisition Corp (the “Company”) was incorporated in Delaware on December 9, 2020. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, or the “Securities Act,” as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, the Company had not commenced any operations. All activity for the period from December 9, 2020 (inception) through June 30, 2023 relates to the Company’s formation and the initial public offering (“Initial Public Offering” or “IPO”) described below, and, after our Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after completion of the Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its year end.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sponsor and Financing:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registration statement for the Company’s IPO was declared effective on February 10, 2022 (the “Effective Date”). On February 15, 2022, the Company consummated the IPO of 7,500,000 units (the “Units” and, with respect to the common stock included in the Units sold, the “Public Shares”), at $10.00 per Unit, generating proceeds of $75,000,000, which is described in Note 3. Additionally, the underwriter fully exercised its option to purchase 1,125,000 additional Units, for which the Company received cash proceeds of $11,250,000. Simultaneously with the closing of the IPO, the Company consummated the sale of 505,000 units (the “Private Placement Units”) at a price of $10.00 per unit generating proceeds of $5,050,000 in a private placement to HNRAC Sponsors, LLC, the Company’s sponsor (the “Sponsor”) and EF Hutton (formerly Kingswood Capital Markets) (“EF Hutton”) that is described in Note 4 (“Related Party Transactions - Private Placement Units”). The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the Private Placement Units, although substantially all of the net proceeds are intended to be generally applied toward consummating the Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs amounted to $4,793,698, comprised of $1,725,000 of underwriting discount, $2,587,500 of deferred underwriting fee, and $481,198 of other offering costs. In addition, $1,368,050 of cash from the IPO was held outside of the Trust Account (as defined below) and is available for working capital purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The Trust Account:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funds from the Initial Public Offering were placed in a trust account (the “Trust Account”). The Trust Account shall invest only in U.S. government treasury bills with a maturity of one hundred eighty (180) days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940 which invest only in direct U.S. government obligations. Funds will remain in the Trust Account until the earlier of (i) the consummation of the Business Combination or (ii) the distribution of the Trust Account as described below. The remaining proceeds outside the Trust Account may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s amended and restated certificate of incorporation provides that, other than the withdrawal of interest to pay taxes, none of the funds held in the Trust Account will be released until the earlier of: (i) the completion of the Business Combination; (ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if it does not complete its initial business combination within 12 months (or within 18 months if we extend the period of time to consummate a business combination, as described in more detail in the prospectus) from the closing of the Initial Public Offering (the “Combination Period”) or (B) with respect to any other provision relating to stockholders’ rights or pre-business combination activity; or (iii) the redemption of 100% of the shares of common stock previously included in the Units sold in the Initial Public Offering if the Company is unable to complete a Business Combination within 12 months from the closing of the Initial Public Offering (subject to the requirements of law).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business Combination:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering, although substantially all of the net proceeds of the Initial Public Offering are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the trust account (excluding taxes payable on the interest earned on the trust account) at the time of the signing of a definitive agreement in connection with the Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, after signing a definitive agreement for a Business Combination, will either (i) seek stockholder approval of the Business Combination at a meeting called for such purpose in connection with which stockholders holding common stock may seek to redeem their shares, regardless of whether they vote for or against the Business Combination, for cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the initial Business Combination, including interest but less taxes payable, or (ii) provide stockholders holding common stock with the opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount in cash equal to their pro rata share of the aggregate amount then on deposit in the Trust Account as of two business days prior to commencement of the tender offer, including interest but less taxes payable. As a result, shares of common stock will be recorded at their redemption amount and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decision as to whether the Company will seek stockholder approval of the Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or under the NYSE American rules. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the outstanding shares of common stock voted are voted in favor of the Business Combination. However, in no event will the Company redeem its public shares of common stock in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of the Business Combination. In such case, the Company would not proceed with the redemption of its public shares of common stock and the related Business Combination, and instead may search for an alternate Business Combination. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023, the Company had $813,177 in cash and a working capital deficit of $1,699,274, which excludes franchise and income taxes payable as the net amounts can be paid from the interest earned in the Trust Account. The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. On February 5, 2023, the Company received notice from the Sponsor of its intention to extend the Combination period by three months until May 15, 2023. On February 8, 2023 in accordance with the Company’s then-effective amended and restated certificate of incorporation, the Sponsor’s designee deposited $862,500 into the Company’s trust account in connection with the extension. On May 11, 2023, the stockholders of the Company approved, and the Company filed with the Secretary of State of Delaware, an amendment to the Company’s certificate of incorporation to extend the date by which the Company must consummate its initial Business Combination from May 15, 2023 by up to six (6) one-month extensions to November 15, 2023, provided that the Sponsor deposits into the Trust Account the lesser of (x) $120,000, or (y) $0.04 per share for each public share of common stock outstanding as of the applicable deadline for each such one-month extension until November 15, 2023, unless the closing of the Company’s initial Business Combination shall have occurred, in exchange for a non-interest bearing, unsecured promissory note payable upon consummation of the initial Business Combination. On May 11, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to June 15, 2023. On June 9, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to July 15, 2023. On July 11, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to August 15, 2023. On August 7, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to September 15, 2023. In the event the Company does not complete a Business Combination by September 15, 2023, or within an additional two months from that date if the available extensions are exercised, the Company is required to redeem the public shares sold in the Initial Public Offering. Additionally, the Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2023 in connection with the stockholder vote for the amendment to the Company’s certificate of incorporation, a total of 4,115,597 Public Shares for an aggregate redemption amount of $43,318,207 were redeemed from the Trust Account by the stockholders of the Company. The Company also withdrew a total of $711,204 from the Trust Account to pay franchise and federal income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the Initial Public Offering price per Unit in the Initial Public Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to protect the amounts held in the trust account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the trust account to below (i) $10.00 per public share or (ii) such lesser amount per public share held in the trust account as of the date of the liquidation of the trust account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the trust account and except as to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (excluding its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account for the benefit of the Public Stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management is currently evaluating the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inflation Reduction Act of 2022</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases (including redemptions) of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Excise Tax Liability</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2023, in connection with the stockholder vote for the amendment to the Company’s certificate of incorporation, a total of 4,115,597 Public Shares for an aggregate redemption amount of $43,318,207 were redeemed from the Trust Account by the stockholders of the Company. As a result of the redemption of common stock on May 11, 2023, the Company recognized an estimated liability for the excise tax of $436,665 on the Company’s condensed balance sheet pursuant to the 1% excise tax under the IR Act. The liability does not impact the condensed statements of operations and is offset against additional paid-in capital or accumulated deficit if additional paid-in capital is not available. This excise tax liability can be offset by future share issuances within the same fiscal year which will be evaluated and adjusted in the period in which the issuances occur. Should the Company liquidate prior to December 31, 2023, the excise tax liability will not be due. The Company will not use funds in trust in connection with the payment of any excise tax liabilities imposed by the Inflation Reduction Act of 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going Concern Considerations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2023, the Company had $813,177 in cash and a working capital deficit of $1,699,274, which excludes franchise and income taxes payable as the net amounts can be paid from the interest earned in the Trust Account. The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. On February 5, 2023, the Company received notice from the Sponsor of its intention to extend the Combination period by three months until May 15, 2023. On February 8, 2023 in accordance with the Company’s then-effective amended and restated certificate of incorporation, the Sponsor’s designee deposited $862,500 into the Company’s trust account in connection with the extension. On May 11, 2023, the stockholders of the Company approved, and the Company filed with the Secretary of State of Delaware, an amendment to the Company’s certificate of incorporation to extend the date by which the Company must consummate its initial Business Combination from May 15, 2023 by up to six (6) one-month extensions to November 15, 2023, provided that the Sponsor deposits into the Trust Account the lesser of (x) $120,000, or (y) $0.04 per share for each public share of common stock outstanding as of the applicable deadline for each such one-month extension until November 15, 2023, unless the closing of the Company’s initial Business Combination shall have occurred, in exchange for a non-interest bearing, unsecured promissory note payable upon consummation of the initial Business Combination. On May 11, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to June 15, 2023. On June 9, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to July 15, 2023. On July 11, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to August 15, 2023. On August 7, 2023, the Sponsor’s designee deposited $120,000 into the Trust Account, extending the date by which the Company must consummate its initial Business Combination to September 15, 2023. In the event the Company does not complete a Business Combination by September 15, 2023, or within an additional three months from that date if the available extensions are exercised, the Company is required to redeem the public shares sold in the Initial Public Offering. Additionally, the Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1125000	shares
	hnra	Cash Received CashReceived	11250000	usd
	hnra	Transaction Costs TransactionCosts	4793698	usd
	hnra	Underwriting Discount UnderwritingDiscount	1725000	usd
	hnra	Underwriting Fees underwritingFees	2587500	usd
CY2023Q2	us-gaap	Other Ownership Interests Offering Costs OtherOwnershipInterestsOfferingCosts	481198	usd
	hnra	Public Shares Percent PublicSharesPercent	1	pure
	us-gaap	Workers Compensation Discount Percent WorkersCompensationDiscountPercent	1	pure
CY2023Q2	us-gaap	Fair Value Investments Entities That Calculate Net Asset Value Per Share Percent Arbitrage Investments FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentArbitrageInvestments	0.80	pure
CY2023Q2	us-gaap	Tangible Capital Required For Capital Adequacy TangibleCapitalRequiredForCapitalAdequacy	5000001	usd
CY2023Q2	us-gaap	Cash Cash	813177	usd
CY2023Q2	hnra	Working Capital WorkingCapital	1699274	usd
CY2023Q2	hnra	Public Shares PublicShares	4115597	shares
CY2023Q2	hnra	Aggregate Value AggregateValue	43318207	usd
CY2023Q2	hnra	Trust Account TrustAccount	711204	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01	pure
CY2023Q2	hnra	Working Capital Deficit WorkingCapitalDeficit	813177	usd
CY2023Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	1699274	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation:</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Condensed Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the period presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2023. The interim results for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.</span></p>
CY2023Q2	hnra	Aggregate Shares2 AggregateShares2	6847500	shares
CY2023Q2	hnra	Warrants To Purchase WarrantsToPurchase	1484250	shares
CY2023Q2	us-gaap	Cash Cash	813177	usd
CY2022Q4	us-gaap	Cash Cash	75612	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	103338	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-325750	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	212066	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-493994	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	6612930	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	8625000	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	7618965	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	6433011	shares
CY2023Q2	hnra	Basic Net Loss Per Redeemable Common Stock BasicNetLossPerRedeemableCommonStock	0.02
CY2022Q2	hnra	Basic Net Loss Per Redeemable Common Stock BasicNetLossPerRedeemableCommonStock	-0.04
	hnra	Basic Net Loss Per Redeemable Common Stock BasicNetLossPerRedeemableCommonStock	0.03
	hnra	Basic Net Loss Per Redeemable Common Stock BasicNetLossPerRedeemableCommonStock	-0.08
CY2023Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-336141	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-154946	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-622483	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-284829	usd
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3006250	shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3006250	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3006250	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2950180	shares
CY2023Q2	hnra	Basic Net Loss Per Nonredeemable Common Stock BasicNetLossPerNonredeemableCommonStock	-0.11
CY2022Q2	hnra	Basic Net Loss Per Nonredeemable Common Stock BasicNetLossPerNonredeemableCommonStock	-0.05
	hnra	Basic Net Loss Per Nonredeemable Common Stock BasicNetLossPerNonredeemableCommonStock	-0.21
	hnra	Basic Net Loss Per Nonredeemable Common Stock BasicNetLossPerNonredeemableCommonStock	-0.1
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates:</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
	us-gaap	Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasic	1
CY2022	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	100000	usd
CY2023Q1	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	300000	usd
CY2022Q1	hnra	Short Term Advances ShortTermAdvances	88200	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentration of Credit Risk:</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2023, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	hnra	Federal Depository Insurance Coverage FederalDepositoryInsuranceCoverage	250000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	86250000	usd
CY2022	hnra	Fair Value Of Public Warrant FairValueOfPublicWarrant	5879729	usd
CY2022	hnra	Common Stock Issuance Costs CommonStockIssuanceCosts	4736093	usd
CY2022	hnra	Accretion To Redemption Value AccretionToRedemptionValue	13409184	usd
CY2022	hnra	Redeemable Common Stock RedeemableCommonStock	89043362	usd
	hnra	Redemptions Of Common Stock RedemptionsOfCommonStock	-43318207	usd
	hnra	Accretion To Redemption Value AccretionToRedemptionValue	1723194	usd
	hnra	Redeemable Common Stock RedeemableCommonStock	47448349	usd
CY2022Q1	hnra	Additional Expenses AdditionalExpenses	190202	usd
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	275000	usd
CY2023Q2	hnra	Unamortized Balance Of Prepaid Balance UnamortizedBalanceOfPrepaidBalance	0	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	1.73	pure
CY2022Q2	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	4.52	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Comparability Of Prior Year Financial Data ComparabilityOfPriorYearFinancialData	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent Accounting Pronouncements:</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. The Company adopted this guidance early on January 1, 2023 with no impact to the Company’s financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.</span></p>
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	11.5
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	7500000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	18
	us-gaap	Public Utilities Requested Equity Capital Structure Percentage PublicUtilitiesRequestedEquityCapitalStructurePercentage	0.05	pure
	hnra	Payments For Offering In Cash Percentage PaymentsForOfferingInCashPercentage	0.02	pure
	hnra	Percentage Of Consummation Business Combination PercentageOfConsummationBusinessCombination	0.03	pure
CY2020Q4	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	25000	usd
CY2023Q2	us-gaap	Shares Issued SharesIssued	2875000	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	373750	shares
CY2022Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2501250	shares
CY2023Q2	hnra	Aggregate Share AggregateShare	326250	shares
	hnra	Underwriters Initial Stockholders Percentage UnderwritersInitialStockholdersPercentage	0.2248	pure
CY2023Q2	hnra	Working Capital Loans WorkingCapitalLoans	1000000	usd
CY2022Q4	hnra	Unamortized Balance Of Prepaid Balance UnamortizedBalanceOfPrepaidBalance	37089	usd
CY2023Q2	hnra	Pay To Agreed PayToAgreed	10000	usd
	hnra	Agreement Amount Paid AgreementAmountPaid	30000	usd
CY2023Q2	hnra	Sponsor Advanced Total Amount SponsorAdvancedTotalAmount	35000	usd
CY2021Q4	hnra	Director Equal Amount DirectorEqualAmount	100000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2875000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2875000	shares
CY2022Q1	hnra	Forfeited Shares Outstanding ForfeitedSharesOutstanding	373750	shares
CY2022Q1	hnra	Forfeited Shares Issued ForfeitedSharesIssued	2501250	shares
CY2022Q1	hnra	Founder Shares Outstanding FounderSharesOutstanding	2501250	shares
CY2023Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4509403	shares
CY2023Q2	hnra	Subject To Redemption Per Share SubjectToRedemptionPerShare	10.52
CY2022Q4	hnra	Aggregate Gross Purchase Price AggregateGrossPurchasePrice	150000000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	2000000	usd
CY2023Q2	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.96	pure
	hnra	Common Stock Values CommonStockValues	1500000	usd
	hnra	Underwriting Discount UnderwritingDiscount	1725000	usd
	hnra	Gross Proceeds GrossProceeds	0.02	pure
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	2587500	usd
	hnra	Private Placement Warrants Description PrivatePlacementWarrantsDescription	In the case of the private placement warrants, representative shares issued to EF Hutton, the demand registration rights provided will not be exercisable for longer than five years from the effective date of the registration statement in compliance with FINRA Rule 5110(f)(2)(G)(iv) and the piggyback registration right provided will not be exercisable for longer than seven years from the effective date of the registration statement in compliance with FINRA Rule 5110(f)(2)(G)(v).
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	1	pure
	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	100000000	usd
	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	15000000	usd
CY2023Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	2000000	shares
CY2023Q2	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	1979000	usd
	hnra	Cash Proceeds CashProceeds	1850000	usd
CY2022	hnra	Cash Proceeds CashProceeds	100000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	29000	usd
CY2023Q2	us-gaap	Investment Interest Rate InvestmentInterestRate	0.15	pure
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	11.5
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1979000	shares
	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.12	pure
CY2023Q2	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.90	pure
	hnra	Fair Value Of The Warrants And Redemption FairValueOfTheWarrantsAndRedemption	1459691	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-113469	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-92713	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	314479	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	499058	usd
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	11.5
CY2023Q3	us-gaap	Deposits Deposits	120000	usd
CY2022Q4	hnra	Excise Tax Payables ExciseTaxPayables		usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q2	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium		usd
CY2022Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense		usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022Q2	hnra	Temporary Equity Accretion To Remeasurement Of Redeemable Common Stock To Redemption Value TemporaryEquityAccretionToRemeasurementOfRedeemableCommonStockToRedemptionValue		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable		usd
	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund		usd
	hnra	Interest Withdrawn From Trust Account To Pay For Franchise And Federal Income Taxes InterestWithdrawnFromTrustAccountToPayForFranchiseAndFederalIncomeTaxes		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	hnra	Deferred Offering Cost Paid Directly By Related Party DeferredOfferingCostPaidDirectlyByRelatedParty		usd
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q2	hnra	Diluted Net Loss Per Redeemable Common Stock DilutedNetLossPerRedeemableCommonStock	-0.04
	hnra	Diluted Net Loss Per Redeemable Common Stock DilutedNetLossPerRedeemableCommonStock	-0.08
	hnra	Diluted Net Loss Per Nonredeemable Common Stock DilutedNetLossPerNonredeemableCommonStock	-0.10
CY2023Q2	hnra	Diluted Net Loss Per Nonredeemable Common Stock DilutedNetLossPerNonredeemableCommonStock	-0.11
	hnra	Diluted Net Loss Per Nonredeemable Common Stock DilutedNetLossPerNonredeemableCommonStock	-0.21
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001842556

Files In Submission

Name	View Source	Status
0001213900-23-069060-index-headers.html	Edgar Link	pending
0001213900-23-069060-index.html	Edgar Link	pending
0001213900-23-069060.txt	Edgar Link	pending
0001213900-23-069060-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_hnracq.htm	Edgar Link	pending
f10q0623ex32-1_hnracq.htm	Edgar Link	pending
f10q0623_hnracq.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hnra-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hnra-20230630_cal.xml	Edgar Link	unprocessable
hnra-20230630_def.xml	Edgar Link	unprocessable
hnra-20230630_lab.xml	Edgar Link	unprocessable
hnra-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_hnracq_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EONR
EON Resources Inc. Stock $eonr

2023 Q3 Form 10-Q Financial Statement

#000121390023069060 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EONR EON Resources Inc. Stock $eonr

2023 Q3 Form 10-Q Financial Statement

#000121390023069060 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EONR
EON Resources Inc. Stock $eonr